Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06235164
Other study ID # 2023KY160
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date December 30, 2025

Study information

Verified date January 2024
Source Fujian Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the safety and effectiveness of laparoscopic gastrectomy (LG) following neoadjuvant immunochemotherapy (nICT)


Description:

comparing the radiological response, pathological response rate, perioperative outcomes, and early recurrence between the two groups.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 585
Est. completion date December 30, 2025
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Age: 18-85 years of age - Gastric adenocarcinoma was confirmed by pathology# including histology or cytology## - CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and/or N+ and M0 before operation. - measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1.#CT scan of tumor lesion length=10mm#CT scan short diameter=15mm#scan slice thicknes 5mm# - ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores; - the expected survival time is more than 12 weeks - the main organ function is normal, which should meet the following criteria: (1) blood routine examination standards should be met#no blood transfusion within 14 days# a#HB= 100g/L b. WBC=3×109/L c. ANC=1.5×109/L d. PLT=100×109/L #2#biochemical examination shall comply with the following criteria# 1. BIL#1.5 normal upper limit ULN 2. ALT and AST#2.5 ULN,GPT=1.5×ULN 3. Cr=1 ULN#CCR#creatinine clearance rate#60ml/min(Cockcroft Gault formula) - women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test# - No other clinical studies were conducted before and during the treatment - participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up. Exclusion Criteria: - Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy - Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for larger abdominal surgery - patients with metastasis - Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma/allergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin - A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation - Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection - pregnant or lactating women - The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg) - With # magnitude of coronary heart disease, arrhythmia (including QTc protracted between male > 450 ms, women > 470 ms) and cardiac insufficiency - Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and unresected gastric primary tumor; patients with the risk of bleeding should take the gastroscopy test, if it is the gastric cancer, and researchers believe that may results in massive digestive tract hemorrhage#coagulation dysfunction (INR(international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ULN), with bleeding tendency; - Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure (2) above unstable angina pectoris (3) occurred within 1 year (4) have clinical significance of myocardial infarction (mi) room sex or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled - History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia - Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g); - A person who has previously been allergic to any component of camrilizumab or to any component of the drug under study - The researchers consider those who were not suitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
Drug: Sintilimab, Nivolumab, and Camrelizumab,One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2. Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2. Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2. Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time

Locations

Country Name City State
China Fujian Medical University Union Hospital Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary pathological complete response pathological complete response (pCR) 4 months
Secondary major pathological response major pathological response#MPR 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT05545436 - Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05524974 - Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes Phase 2
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT03961373 - Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer Phase 3
Completed NCT02192983 - A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer. N/A
Not yet recruiting NCT05610332 - Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes Phase 3
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT02365896 - Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Not yet recruiting NCT06459921 - Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer Phase 2
Recruiting NCT05141747 - A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. Phase 2
Active, not recruiting NCT06277453 - Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
Recruiting NCT05528367 - Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT04792515 - Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT03322969 - Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Phase 2
Recruiting NCT02302794 - A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery Phase 3